Allianz Asset Management GmbH Boosts Holdings in Vir Biotechnology, Inc. $VIR

Allianz Asset Management GmbH grew its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 6.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 327,700 shares of the company’s stock after acquiring an additional 19,000 shares during the quarter. Allianz Asset Management GmbH owned 0.24% of Vir Biotechnology worth $1,652,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its stake in shares of Vir Biotechnology by 9.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,374,874 shares of the company’s stock worth $8,909,000 after acquiring an additional 122,219 shares in the last quarter. Aberdeen Group plc raised its stake in shares of Vir Biotechnology by 45.3% during the second quarter. Aberdeen Group plc now owns 1,006,891 shares of the company’s stock worth $5,075,000 after acquiring an additional 313,699 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Vir Biotechnology by 43.6% during the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock worth $4,813,000 after acquiring an additional 225,544 shares in the last quarter. Clarius Group LLC raised its stake in shares of Vir Biotechnology by 979.7% during the second quarter. Clarius Group LLC now owns 617,535 shares of the company’s stock worth $3,112,000 after acquiring an additional 560,342 shares in the last quarter. Finally, Woodline Partners LP raised its stake in shares of Vir Biotechnology by 245.6% during the first quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock worth $3,024,000 after acquiring an additional 331,701 shares in the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

VIR has been the topic of several analyst reports. Raymond James Financial initiated coverage on shares of Vir Biotechnology in a research note on Friday, July 11th. They issued an “outperform” rating on the stock. Bank of America raised shares of Vir Biotechnology from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $12.00 to $14.00 in a research note on Wednesday, August 27th. Evercore ISI initiated coverage on shares of Vir Biotechnology in a research note on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Tuesday, October 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Vir Biotechnology in a research note on Monday, September 15th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $17.30.

Insider Activity at Vir Biotechnology

In other news, major shareholder Endurance (Cayman) Ltd Svf sold 154,383 shares of the business’s stock in a transaction on Thursday, October 23rd. The shares were sold at an average price of $5.99, for a total transaction of $924,754.17. Following the sale, the insider owned 14,711,635 shares in the company, valued at approximately $88,122,693.65. The trade was a 1.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders have sold 2,038,406 shares of company stock worth $12,090,468. Insiders own 16.00% of the company’s stock.

Vir Biotechnology Trading Up 3.5%

Shares of Vir Biotechnology stock opened at $5.98 on Friday. The company’s fifty day simple moving average is $5.32 and its two-hundred day simple moving average is $5.29. The company has a market cap of $830.72 million, a P/E ratio of -1.50 and a beta of 1.27. Vir Biotechnology, Inc. has a 12-month low of $4.16 and a 12-month high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last announced its earnings results on Wednesday, August 6th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The business had revenue of $1.21 million for the quarter, compared to the consensus estimate of $2.38 million. During the same quarter last year, the firm posted ($1.02) EPS. The business’s quarterly revenue was down 60.5% on a year-over-year basis. Analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).